Brief: Oncolytics Biotech Provides Positive Safety Update On Phase 1/2 Gastrointestinal Cancer Trial
02/02/2022 12:14
Feb 2 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PROVIDES POSITIVE SAFETY UPDATE ON THE
PANCREATIC CANCER COHORT OF ITS MULTI-INDICATION PHASE 1/2
GASTROINTESTINAL CANCER TRIAL
* ONCOLYTICS BIOTECH INC - INDEPENDENT SAFETY REVIEW
COMPLETED
WITH NO TOXICITY CONCERNS
* ONCOLYTICS BIOTECH INC - SAFETY RUN-IN FOR TRIAL'S
THIRD-LINE
METASTATIC COLORECTAL CANCER COHORT REMAINS ONGOING
Source text for Eikon: ID:nCNW296zFa
Further company coverage: ONC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer